IMS 2022 | The long-term safety and efficacy of ibrutinib monotherapy in patients with previously-treated WM
Steven Treon
• 25 Aug 2022
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the long-term safety and efficacy of ibrutinib monotherapy in patients with previously treated Waldenström’s macroglobulinemia (WM), including those with MYD88 and CXCR4 mutations. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
